Medifast (NYSE:MED) Full Year 2024 Results

Key Financial Results

• Revenue: US$602.5m (down 44% from FY 2023).
• Net income: US$2.09m (down 98% from FY 2023).
• Profit margin: 0.3% (down from 9.3% in FY 2023).
• EPS: US$0.19 (down from US$9.13 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Medifast EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates.

In the last 12 months, the only revenue segment was OPTAVIA contributing US$602.5m. The largest operating expense was General & Administrative costs, amounting to US$410.5m (93% of total expenses). Explore how MED's revenue and expenses shape its earnings.

Looking ahead, revenue is expected to decline by 15% p.a. on average during the next 2 years, while revenues in the Personal Products industry in the US are expected to grow by 3.6%.

Performance of the American Personal Products industry.

The company's shares are down 4.9% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Medifast (at least 1 which shouldn't be ignored), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.